Influenza Vaccination in Patients Living With HIV in the Northern Region

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

124 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-10

Study Completion Date

2020-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anyone living with the Human Immunodeficiency Virus (HIV) has an indication for annual influenza vaccination. (Vaccination schedule and vaccination recommendations 2019). Influenza is a viral infection that has a significant impact on the health care system. However, vaccination coverage in France is still insufficient with regard to the objectives set at 75% by the WHO and the European Commission. For the 2019-2020 seasonal influenza vaccination campaign, flu vaccination by volunteer pharmacists has become possible throughout the country. Studies that have estimated vaccination coverage among HIV-positive populations are rare and show very low rates.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients

NCT01017172

HIV-1 Infection Cancer Immunosuppression

UNKNOWN PHASE4

Influenza Vaccine in HIV

NCT00764998

Influenza HIV

COMPLETED PHASE3

Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals

NCT01381029

Influenza, Human Human Immunodeficiency Virus I Infection

COMPLETED

Immune Response to Influenza Vaccine in HIV-Infected Individuals

NCT00069914

HIV Infections

COMPLETED

Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV

NCT05085145

People Living With HIV COVID-19 Vaccine

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cross-sectional study via a self-questionnaire given to all HIV-infected patients coming for a scheduled consultation as part of their HIV follow-up in the spring of 2020. Non-opposition letter given to the patient. Collection of data a posteriori from the medical file recorded in the eNadis patient file.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any adult person living with HIV presenting for a follow-up consultation in the spring of 2020
* People who do not read French may participate if they wish with the help of a medical or paramedical staff member.
* Patient did not object